It is important to note that some anti-CD47 antibodies can by themselves opsonize tumor cells, depending on their ability to still bind Fc-receptors, and hence act as a two-edged sword, i.e., by opsonizing tumor cells for phagocytosis and simultaneously inhibiting CD47-SIRPα interactions. Here, SIRPA is linked to neoplasm.